Related Experiment Videos
Intensive immunosuppression in intractable rheumatoid arthritis
British Journal of Rheumatology
|November 1, 1986
Summary
Antilymphocyte globulin combined with steroids and cytotoxic agents showed initial benefits for rheumatoid arthritis patients. However, sustained improvement was limited despite ongoing treatment.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and damage.
- Intractable RA cases often require combination therapies to manage symptoms and disease progression.
Purpose of the Study:
- To evaluate the efficacy and sustainability of a combination therapy for intractable rheumatoid arthritis.
- To assess the impact of antilymphocyte globulin, prednisolone, and azathioprine on RA symptoms and inflammatory markers.
Main Methods:
- A cohort of twelve patients with intractable RA received a treatment regimen.
- Treatment included antilymphocyte globulin (ALG), prednisolone, and a cytotoxic agent (typically azathioprine).
- Patients were monitored for one year, with assessments at baseline, 6 weeks, and 3 months.
Main Results:
- Significant improvements were observed in early-morning stiffness, grip strength, and reduced vasculitis/nodule severity at 6 weeks and 3 months (p < 0.05).
- These benefits were largely not sustained beyond the initial assessment periods despite continued therapy.
- A sustained increase in hemoglobin and decrease in erythrocyte sedimentation rate (ESR) was noted throughout the study.
Conclusions:
- Combination therapy with ALG, steroids, and cytotoxic agents offers short-term symptom relief in intractable RA.
- Long-term sustained efficacy of this regimen for RA symptom control appears limited.
- The regimen demonstrated sustained effects on hematological markers (hemoglobin and ESR) in RA patients.